Office of Research
Clinical Trials

Leading the Future of Clinical Medicine
The College of Medicine is a hub for groundbreaking clinical research. With over 30 specialized research units, our teams are dedicated to translating laboratory discoveries into life-saving clinical applications. From neurology to oncology, we provide the infrastructure and expertise necessary to push the boundaries of modern medicine.

Browse our Research Units below to view current study listings.

Clinical Trials Search

Davendra Sohal, MD, MPH

Davendra Sohal, MD, MPH

Gastrointestinal Cancer

Phase 1

DB 1324 in Gastrointestinal Cancer

This first-in-human study will test DB-1324 in people with advanced or metastatic gastrointestinal (GI) cancers. The study has two main phases. Phase 1 uses dose escalation and expansion steps to find a safe and tolerable dose and to learn how the drug behaves in the body. Phase 2 will further check safety and look for signs the drug can help certain GI cancers. Participants will get DB-1324 regularly until their disease worsens, they have unacceptable side effects, they choose to stop, or another reason for stopping occurs. Researchers will watch for side effects, serious adverse events, and dose-limiting toxicities to find the maximum tolerated dose and recommended doses for later studies. The study will also measure tumor response, how long any responses last, time until progression, and drug levels in the blood. Participants will need to provide tumor tissue or allow a biopsy for testing biomarkers such as CDH17.

This study may be appropriate for those with: Metastatic Cancer

Learn More about DB 1324 in Gastrointestinal Cancer
Davendra Sohal, MD, MPH

Davendra Sohal, MD, MPH

Gastrointestinal Cancer

Phase 1

Study of RAS Inhibitors in GI Tumors

This clinical study is investigating new drugs called RAS inhibitors for treating gastrointestinal cancers, focusing mainly on colorectal and pancreatic cancers. The goal is to see if these drugs are safe, how well they are tolerated by patients, and if they show any early signs of fighting the cancer. Researchers are combining these RAS inhibitors with standard cancer treatments or other new drugs to find the most effective therapy. The study has three main parts, each testing a different combination of drugs: 1. **Part A**: This part looks at RMC-6236 combined with 5-fluorouracil-based treatments in patients who have not received prior treatment for their unresectable or metastatic colorectal cancer or metastatic pancreatic cancer. 2. **Part B**: In this segment, RMC-6236 is paired with cetuximab, and sometimes with mFOLFOX6, for patients with unresectable or metastatic colorectal cancer or those who have either previously treated or newly diagnosed metastatic pancreatic cancer. 3. **Part C**: This section tests RMC-6236 combined with gemcitabine and nab-paclitaxel in patients who have newly diagnosed metastatic pancreatic cancer. Each part of the study is open-label, meaning that both the doctors and the patients know which treatments are being given. The study consists of two phases: Dose Exploration to find the right dose levels and Dose Expansion to further evaluate the selected doses. To join the study, participants must be adults with specific types of cancer and good overall health. They should not have had major surgery 28 days before starting the study, and cannot have certain health issues like primary CNS tumors or GI problems that might affect the drug's absorption. The main outcomes of the study include monitoring for adverse events, understanding how the drug moves through the body, and measuring how well the drug works against the cancer. These measurements will include looking at how long and how well patients respond to the treatment, how long they live without the cancer getting worse, and their overall survival time. The study is currently recruiting participants and holds promise for finding more effective treatments for GI cancers involving mutations in the RAS gene.

This study may be appropriate for those with: Metastatic Cancer

Learn More about Study of RAS Inhibitors in GI Tumors
Bailey Nelson

Bailey Nelson

Gynecologic Cancer | Genitourinary Cancer | Gastrointestinal Cancer

Feasibility of an Oral 5 Strain Probiotic (PGC) for GI Toxicity Mitigation During Pelvic Radiation

The exact mechanism of GI symptoms is elusive, but there is sufficient data to suggest that the intestinal microbiome plays a role in radiation-induced GI injury. This feasibility trial will evaluate whether an oral 5 strain probiotic (PGC) can be safely and effectively administered during pelvic RT. PGC will be supplied by Pendulum Therapeutics. Pendulum has completed trials using PGC in non-cancer conditions. The investigators hypothesize that oral supplementation with PGC for GI toxicity mitigation during pelvic radiation is feasible. The intervention will be considered feasible if probiotic tolerability and patient adherence are appropriate. An overall probiotic adherence rate of ≥ 80% by ≥ 70% of patients will be considered acceptable. If feasible, these results will support evaluation of toxicity mitigation in randomized subsequent Phase II/III trials of PGC supplementation during pelvic radiation.

This study may be appropriate for those with: Metastatic Cancer

Learn More about Feasibility of an Oral 5 Strain Probiotic (PGC) for GI Toxicity Mitigation During Pelvic Radiation
Davendra Sohal, MD, MPH

Davendra Sohal, MD, MPH

Gastrointestinal Cancer

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.

This study may be appropriate for those with: Newly Diagnosed Cancer

Learn More about Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors